spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Lotus 

 HSMN NewsFeed - 7 Jun 2022
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 24 May 2022
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 21 Dec 2021
Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 30 Sep 2021
OLUMIANT(R) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Biopharmaceuticals
 HSMN NewsFeed - 16 Aug 2021
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 17 Nov 2020
Boston Scientific Announces LOTUS Edge(TM) Aortic Valve System Voluntary Recall and Product Discontinuation
Devices Interventional Cardiology Product Recall
 HSMN NewsFeed - 28 Sep 2020
Boston Scientific Launches ACURATE neo2(TM) Aortic Valve System in Europe
Devices Interventional Cardiology Product Launch
 HSMN NewsFeed - 26 Jun 2020
Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2019
Boston Scientific Announces Scheduled Presentations at Transcatheter Cardiovascular Therapeutics 2019
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Dec 2018
Lilly Announces Positive Top-Line Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 13 Dec 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Dec 2018
Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Devices Cardiology Litigation
 HSMN NewsFeed - 10 Sep 2018
Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz(R) and Tremfya(R) in Patients with Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals
 HSMN NewsFeed - 28 Jun 2018
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
Biopharmaceuticals
 HSMN NewsFeed - 28 Mar 2018
Boston Scientific Prevails In U.K. Edwards Lifesciences Litigation
Devices Cardiology Litigation
 HSMN NewsFeed - 19 Feb 2018
AAD 2018: Treatment with Lilly's Taltz(R) (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 13 Feb 2018
Lilly Announces Positive Top-Line Phase 3 Results for Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2017
Long-Term Use of Lilly's Taltz(R) (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
Biopharmaceuticals
 HSMN NewsFeed - 16 Jun 2017
EULAR 2017: Lilly's Taltz(R) (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2017
The Boston Scientific LOTUS(TM) Valve System Demonstrated Superior Efficacy to CoreValve(R) in Global REPRISE III Trial at One Year
Devices Interventional Cardiology
 HSMN NewsFeed - 16 May 2017
Boston Scientific Closes Symetis Acquisition
Devices Interventional Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 30 Mar 2017
Symetis and Boston Scientific Reach USD 435 Million Purchase Agreement
Devices Interventional Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 30 Mar 2017
Boston Scientific Announces Agreement to Acquire Symetis
Devices Interventional Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 13 Dec 2016
Boston Scientific Closes Acquisition of Advanced Biological Tissue Capabilities and Acquires Common Shares of Neovasc, Inc.
Devices Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 2 Dec 2016
Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities
Devices Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 10 Oct 2016
Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer
Devices Cardiology Personnel
 HSMN NewsFeed - 29 Sep 2016
Avita Medical Signs Exclusive Distributor Deal in Iran
Devices Regenerative Medicine Distribution
 HSMN NewsFeed - 19 Sep 2016
Boston Scientific Receives CE Mark For LOTUS Edge(TM) Valve System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 13 May 2016
Boston Scientific Announces Schedule of Presentations at EuroPCR 2016
Devices Interventional Cardiology
 HSMN NewsFeed - 8 Oct 2015
Boston Scientific Announces Additional Investment And Right To Acquire MValve Technologies
Devices Interventional Cardiology Venture Capital
 HSMN NewsFeed - 20 May 2015
Post-Market Study Evaluating The Boston Scientific Lotus(TM) Valve System Demonstrates Extremely Low PVL Rates
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Nov 2014
Agilis Biotherapeutics Names Former Shire Executive Dr. Gregory Robinson as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Dec 2013
Boston Scientific Elects David Roux To Its Board of Directors
Devices Personnel
 HSMN NewsFeed - 15 Nov 2013
Boston Scientific Announces First Commercial Implants Of The Lotus(TM) Valve System in Europe
Devices Interventional Cardiology Product Launch
 HSMN NewsFeed - 28 Oct 2013
Boston Scientific Receives CE Mark For Lotus(TM) Valve System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 17 Oct 2013
OncoMed Pharmaceuticals Appoints Michael Wyzga to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Sep 2013
Boston Scientific Reports Favorable Six-Month Results From Lotus(TM) Valve System Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 17 May 2013
Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013
Devices Interventional Cardiology
 HSMN NewsFeed - 14 May 2013
Third Rock Ventures Expands and Strengthens Team
Biopharmaceuticals Devices Venture Capital Personnel
 HSMN NewsFeed - 23 Oct 2012
Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Oct 2012
First Patient Enrolled in REPRISE II TAVR Clinical Trial to Evaluate the Safety and Performance of the Lotus™ Valve System
Devices Cardiology
 HSMN NewsFeed - 31 May 2012
N-of-One Appoints Christine Cournoyer Chief Executive Officer
Diagnostics Personalized Medicine Oncology Personnel
 HSMN NewsFeed - 15 May 2012
Boston Scientific Announces Positive Data From Lotus(TM) Transcatheter Aortic Valve Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 10 May 2012
Boston Scientific Announces Schedule For EuroPCR 2012
Devices Interventional Cardiology
 HSMN NewsFeed - 3 May 2012
Pink Lotus Breast Center to Launch IORT Program Featuring iCAD’s Xoft Radiation Therapy System for Breast Cancer Patients
Devices Oncology
 HSMN NewsFeed - 27 Apr 2012
Watson Announces Restructuring of Senior Leadership to Support Expanded Global Businesses
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2012
Boston Scientific Completes Enrollment in Clinical Trial to Evaluate Lotus(TM) Aortic Valve System
Devices Interventional Cardiology
 HSMN NewsFeed - 27 Mar 2012
Third Rock Ventures Appoints Mark A. Goldsmith, M.D., Ph.D., as Venture Partner
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 1 Nov 2011
Boston Scientific Announces Schedule of Events at TCT Scientific Symposium
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Jan 2011
Boston Scientific Completes Acquisition of Sadra Medical
Devices Interventional Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 19 Nov 2010
Boston Scientific to Acquire Sadra Medical
Devices Interventional Mergers & Acquisitions
 HSMN NewsFeed - 4 Aug 2010
Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jun 2010
Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform
Devices Oncology
 HSMN NewsFeed - 27 Jan 2010
Juvaris BioTherapeutics Completes Second Close on $25 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 Sep 2009
Juvaris BioTherapeutics Announces First Close on $25 million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Jul 2009
Rapid Micro Biosystems Closes $18.6M Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 May 2009
Sadra Medical Raises $30 Million
Devices Interventional Cardiology Venture Capital
 HSMN NewsFeed - 6 Feb 2009
ROXRO Announces FDA Accepts for Review NDA for ROX-888 for the Management of Acute Moderate to Severe Pain
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 23 Sep 2008
KaloBios Raises $20 Million in Series D Venture Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Dec 2007
FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
Biopharmaceuticals
 HSMN NewsFeed - 11 Oct 2007
Xcellerex Raises $31 Million in Series C Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 11 Jul 2007
Sadra Medical Announces Successful Clinical Use of the First Retrievable, Repositionable Transcatheter Aortic Heart Valve
Devices Interventional Cardiology
 HSMN NewsFeed - 8 Jan 2007
Juvaris Announces First Round Closing of Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 Oct 2006
Sadra Medical Raises $19 Million in Series B Financing
Devices Cardiology Venture Capital
 HSMN NewsFeed - 2 Oct 2006
AGA Medical Appoints Brigid A. Makes Chief Financial Officer
Devices Interventional Cardiology Personnel
Return to NewsFeed  

 Additional items found! 8

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 8 additional stories matching:
Lotus
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!